Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kirthik Parthasarathy

Obstetrics & Gynecology West Reading, PA Medical Doctor

NPI 1104263441 CMS profile 821557

6Th Avenue & Spruce Street, West Reading, PA 19611

Open in the dashboard

General payments

$103,095

140 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kirthik Parthasarathy of West Reading, PA is reported in the CMS Open Payments database as having received $103,095 across 140 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,483 12
2024 General $23,054 26
2023 General $20,378 27
2022 General $39,729 45
2021 General $11,718 17
2019 General $733 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kirthik Parthasarathy
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Kirthik Parthasarathy were reported at $7,483. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Kirthik Parthasarathy Obstetrics & Gynecology median Middle half National median
2019 $733 $172 $62–$391 $163
2020 $0 $94 $36–$222 $114
2021 $11,718 $136 $42–$369 $132
2022 $39,729 $160 $50–$433 $149
2023 $20,378 $169 $56–$423 $160
2024 $23,054 $152 $50–$371 $164
2025 $7,483 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Applied Medical Resources Corporation $101,767 112 payments
  2. AbbVie, Inc. $397 7 payments
  3. DySIS Medical, Inc. $198 1 payment
  4. Astellas Pharma US Inc $124 1 payment
  5. Biohaven Pharmaceuticals, Inc. $124 1 payment
  6. Pfizer Inc. $103 6 payments
  7. Mayne Pharma Inc. $94 1 payment
  8. Hologic, LLC $94 2 payments
  9. Intuitive Surgical, Inc. $74 3 payments
  10. TherapeuticsMD, Inc. $45 2 payments
  11. Other $75 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $82,000 31 payments
  2. Travel and Lodging $15,303 37 payments
  3. Food and Beverage $3,544 63 payments
  4. Consulting Fee $2,213 7 payments
  5. Education $35 2 payments
Products named General payments · program years 2019–2025
  1. GelPOINT V-Path Specialty Access $42,493 37 payments
  2. GelPOINT V-Path Specialty Access $42,441 33 payments
  3. GELPOINT V-PATH Specialty Access $23,961 20 payments
  4. Ultra 2.0 $198 1 payment
  5. HUMIRA $133 3 payments
  6. Orilissa $125 2 payments
  7. NURTEC ODT $124 1 payment
  8. Veozah $124 1 payment
  9. Myosure $94 2 payments
  10. Da Vinci Surgical System $74 3 payments
  11. Other $252 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

193

Median for Obstetrics & Gynecology: 65

Drug cost

$11,540

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

52.8%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Premarin Estrogens, Conjugated Brand 11 $5,482
Estradiol (Once Weekly) Estradiol Brand 44 $2,250
Estradiol Generic 46 $2,046
Progesterone Progesterone, Micronized Brand 34 $1,220
Norethindrone Acetate Generic 14 $294
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 13 $155
Fluconazole Generic 17 $72
Alendronate Sodium Generic 14 $21

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$9,062

Medicare's payments for the services billed

Medicare patients

59

Average age 71

Services billed

119

59 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 58%
Depression 37%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

140 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record